Page last updated: 2024-12-07
N-methyl-N-(3-pyridylmethyl)amine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 88393 |
| CHEMBL ID | 357101 |
| CHEBI ID | 194978 |
| SCHEMBL ID | 46656 |
Synonyms (62)
| Synonym |
|---|
| AC-2640 |
| n-methyl-3-pyridinemethylamine |
| methyl(pyridin-3-ylmethyl)amine |
| NCIOPEN2_000255 |
| 20173-04-0 |
| nsc-66532 |
| 3-pyridinemethanamine, n-methyl- |
| nsc63901 |
| nsc-63901 |
| nsc66532 |
| 3-picolylmethylamine |
| bdbm50138486 |
| methyl-pyridin-3-ylmethyl-amine |
| n-methyl(pyridin-3-yl)methanamine |
| CHEMBL357101 , |
| AKOS000264146 |
| n-methyl-n-(3-pyridylmethyl)amine , |
| F2158-0857 |
| HMS1718B12 |
| CHEBI:194978 |
| n-methyl-1-pyridin-3-ylmethanamine |
| A4398 |
| n-methyl-1-(pyridin-3-yl)methanamine |
| 3-(n-methylaminomethyl)pyridine |
| nsc 66532 |
| 3-(methylaminomethyl)pyridine |
| nsc 63901 |
| einecs 243-561-9 |
| methyl[(pyridin-3-yl)methyl]amine |
| EN300-07963 |
| n-methyl-3-pyridinemethanamine |
| GEO-01922 |
| (3-methylaminomethyl)pyridine |
| FT-0637954 |
| PS-4696 |
| AM20050925 |
| AB01384 |
| 3-[(methylamino)methyl]pyridine |
| SCHEMBL46656 |
| mfcd00023610 |
| SY002368 |
| n-methyl-1-(3-pyridyl)methanamine |
| n-methyl-n-(3-pyridylmethyl) amine |
| 3-(methylamino-methyl)-pyridine |
| 3-(methylaminomethyl) pyridine |
| n-methyl-n-(3-pyridinylmethyl)amine |
| n-methyl-n-3-pyridylmethylamine |
| 3-methylaminomethyl pyridine |
| methyl-(beta-picolyl)-amine |
| n-methyl-3-picolylamine |
| Q-103417 |
| STR08305 |
| M2257 |
| n-(3-pyridylmethyl)methylamine |
| DTXSID70174005 |
| 3-[(methylamino)methyl]pyridine, 97% |
| Z56963341 |
| NCGC00374071-01 |
| CS-0020099 |
| BCP23374 |
| SB75453 |
| n-methyl-n-(pyridin-3-ylmethyl)amine, 3-picolylmethylamine |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| aralkylamine | An alkylamine in which the alkyl group is substituted by an aromatic group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Neuronal acetylcholine receptor subunit beta-2 | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.1117 | 3.5400 | AID263012 |
| Neuronal acetylcholine receptor subunit alpha-4 | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.1157 | 3.5400 | AID263012 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (47)
Molecular Functions (8)
Ceullar Components (13)
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1345082 | Cytotoxic Profiling in NIH 3T3 Cell Line of Diverse Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1345083 | Cytotoxic Profiling in HEK 293 Cell Line of Diverse Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID146485 | Binding affinity towards nicotinic acetylcholine receptor alpha4-beta2 from rat brain homogenates | 2004 | Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2 | 3-(4-Aminobutyn-1-yl)pyridines: binding at alpha 4 beta 2 nicotinic cholinergic receptors. |
| AID263012 | Affinity to alpha-4-beta-2 AChR | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7 | Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.63
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||